FDA Denies Accelerated Approval to Eli Lilly’s Alzheimer’s Drug
- January 20, 2023
The Food and Drug Administration (FDA) has declined to approve under the agency’s accelerated pathway Eli Lilly and Company’s drug donanemab for treating Alzheimer’s disease, the company announced January 19.
ARTICLE TAGS
You must be logged in to access this content.